Yücel BAŞPINAR, Hasan AKBABA, Selen İSAR, Gülşah EREL AKBABA

Development and characterization of cationicnanoemulsions as non-viral vectors for plasmid DNAdelivery

Gene therapy is a promising approach to treat several diseases including cancer. Unfortunately, free nucleic acids are negatively charged and not stable in blood. Cationic drug delivery systems like cationic nanoemulsions (CNEs) are useful to improve the stability and delivery of nucleic acids like plasmid DNA (pDNA) by increasing the interaction between nucleic acids and negatively charged cell membrane. This study is focused on the development and characterization of two CNEs (CNE 1 and CNE 2) for the delivery of pDNA. The CNEs were prepared with microfluidization by investigating the homogenization duration of 1-10 minutes and the droplet size (DS), polydispersity index (PDI), zeta potential (ZP), complexation with pDNA and cytotoxicity on mouse fibroblast cells L929 were characterized. With increasing the microfluidization duration from 1 to 10 minutes, the DS and PDI decreased and the ZP increased for CNE 1, while for CNE 2 the ZP decreased too. Increasing the microfluidization duration does not lead to beneficial results, thus 1 minute seems to be sufficient for obtaining CNEs with appropriate properties. Both CNEs were able to form a complex in a ratio of 1 µl plasmid and 2 µl CNE. The cytotoxicity studies for CNE 1 and its complex revealed that with increasing the applied dose the viability of the L929 cells decreased to 70%, while for CNE 2 and its complex the viability was reduced to 10%. Based on these results it can be stated that CNE 1 is more appropriate than CNE 2 for pDNA delivery.

PDF

___

[1] Rolland A, Sullivan SM. Mechanisms for Cationic Lipids in Gene Transfer. Pharm Gene Del Sys, Eastern Hemisphere Distribution, New York 2003.
[2] Taira K, Kataoka TN (Eds.). Non-Viral Gene Therapy. Gene Design and Delivery. Springer-Verlag, Tokyo 2005.
[3] Clement J, Kiefer K, Kimpfler A, Garidel P, Peschka-Suss R. Large-scale production of lipoplexes with long shelf-life. Eur J Pharm Biopharm. 2005; 59: 35–43. [CrossRef]
[4] Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci. 2008; 97: 726–745. [CrossRef]
[5] Schuh R, Baldo G, Teixeira H. Nanotechnology applied to treatment of mucopolysaccharidoses. Expert Opin Drug Deliv. 2016; 13: 1709–1718. [CrossRef]
[6] Verissimo LM, Lima LFA, Egito LCM, de Oliveira AG, do Egito EST. Pharmaceutical emulsions: a new approach for gene therapy. J Drug Target 2010; 18: 333–342. [CrossRef]
[7] Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Contr Rel. 2006; 116: 255– 264. [CrossRef]
[8] De Laporte L, Cruz Rea J, Shea LD. Design of modular non-viral gene therapy vectors. Biomat. 2006; 27: 947–954. [CrossRef]
[9] Hara T, Liu F, Liu D, Huang L. Emulsion formulations as a vector for gene delivery in vitro and in vivo. Adv Drug Deliv Rev. 1997; 24: 265–271. [CrossRef]
[10] Liu F, Yang J, Huang L, Liu D. Effect of non-ionic surfactants on the formation of DNA/emulsion complexes and emulsion-mediated gene transfer. Pharm Res. 1996; 13: 1642–1646. [CrossRef]
[11] Teixeira H, Dubernet C, Puisieux F, Benita, S, Couvreur P. Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharm Res. 1999; 16: 30–36.
[12] Ott G, Singh M, Kazzaz J, Briones M, Soenawan E, Ugozzoli M, O’Hagan DT, A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Control Rel. 2002; 79: 1–5. [CrossRef]
[13] Kim TW, Chung H, Kwon IC, Sung HC, Jeong SC. In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion. Mol Cells. 2000; 10: 142–147. [CrossRef]
[14] Zhang S, Xu Y, Wang B, Qiao W, Liu D, Li Z. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Contr Rel. 2004; 100: 165–180. [CrossRef]
[15] Fraga M, Bruxel F, Diel D, de Carvalho TG, Perez CA, Magalhaes-Paniago R, Malachias A, Oliveira MC, Matte U, Teixeira HF. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model. J Contr Rel. 2015; 209: 37–46. [CrossRef]
[16] Yadav S, Gandham SK, Panicucci R, Amiji MM. Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFalpha siRNA in prevention of experimental neuroinflammation. Nanomed. 2016; 12: 987–1002. [CrossRef]
[17] Kang HS, Jin SJ, Myung CS, Hwang SJ, Park JS. Delivery of interleukin-18 gene to lung cancer cells using cationic emulsion. J Drug Target. 2009; 17: 19–28. [CrossRef]
[18] Başpınar Y, Erel Akbaba G, Kotmakçı M, Akbaba H. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer. Int J Pharm. 2019; 566: 149-156. [CrossRef]
[19] Akbaba H, Erel Akbaba G, Kantarcı AG. Development and evaluation of antisense shRNA-encoding plasmid loaded solid lipid nanoparticles against 5-α reductase activity. J Drug Del Sci Tech. 2018; 44: 270–277. [CrossRef]
[20] Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm. 2009; 370: 181–186. [CrossRef]
[21] Baspinar Y, Borchert HH. Penetration and release studies of positively and negatively charged nanoemulsions—Is there a benefit of the positive charge? Int J Pharm. 2012; 430: 247–252. [CrossRef]
[22] Baspinar Y, Keck C, Borchert HH. Development of a positively charged prednicarbate nanoemulsion, Int J Pharm. 2010; 383: 201–208. [CrossRef]
[23] Başpınar Y, Gündoğdu E, Köksal Ç, Karasulu E. Pitavastatin-containing nanoemulsions: Preparation, characterization and in vitro cytotoxicity. J Drug Del Sci Tech. 2015; 29: 117-124. [CrossRef]
[24] Başpınar Y, Gündoğdu E, Karasulu E, Borchert HH. The preparation of prednicarbate nanoemulsions - a comparison of three homogenizers. Nano-Bulletin. 2013; 2: 130102.
[25] Muller RH. Zetapotential und Partikeladung in der Laborpraxis,Wissenschaftliche Verlagsgesellschaft mbH, tuttgart,